Amgen files Enbrel plant sBLA
Executive Summary
Amgen files sBLA Aug. 23 for Enbrel manufacturing facility in Rhode Island. Company expects to begin shipping from the plant immediately after approval, which is projected for first quarter 2003. Rhode Island plant will use same high-yield manufacturing process used at contract manufacturer Boehringer Ingelheim's facility (1"The Pink Sheet" April 29, p. 35). Etanercept shortage continues with 23,000 patients on waiting list as of July 24. Approximately 200,000 potential patients have signed up to receive information on rheumatoid arthritis through Amgen's "RA Access" unbranded TV ad campaign...
You may also be interested in...
Enbrel Shortage Strategies: Clinical Trials Will Provide “Bolus” Of Patients
Immunex' ongoing Enbrel clinical trials will help provide a "bolus" of patients for the rheumatoid arthritis agent once the company expands its commercial capacity for the biologic
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.